JP2003504018A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003504018A5 JP2003504018A5 JP2001508332A JP2001508332A JP2003504018A5 JP 2003504018 A5 JP2003504018 A5 JP 2003504018A5 JP 2001508332 A JP2001508332 A JP 2001508332A JP 2001508332 A JP2001508332 A JP 2001508332A JP 2003504018 A5 JP2003504018 A5 JP 2003504018A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- oligonucleotide
- under conditions
- molecule
- polymerase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 description 49
- 108020004707 nucleic acids Proteins 0.000 description 42
- 102000039446 nucleic acids Human genes 0.000 description 42
- 150000007523 nucleic acids Chemical class 0.000 description 42
- 108091034117 Oligonucleotide Proteins 0.000 description 28
- 239000003112 inhibitor Substances 0.000 description 24
- 239000000203 mixture Substances 0.000 description 21
- 102100034343 Integrase Human genes 0.000 description 20
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 19
- 102000004190 Enzymes Human genes 0.000 description 17
- 108090000790 Enzymes Proteins 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 10
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 10
- 108091028664 Ribonucleotide Proteins 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 238000001668 nucleic acid synthesis Methods 0.000 description 8
- 239000002336 ribonucleotide Substances 0.000 description 8
- 125000002652 ribonucleotide group Chemical group 0.000 description 8
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 239000005547 deoxyribonucleotide Substances 0.000 description 5
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 5
- 208000036142 Viral infection Diseases 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14207299P | 1999-07-02 | 1999-07-02 | |
| US60/142,072 | 1999-07-02 | ||
| PCT/US2000/018256 WO2001002559A1 (en) | 1999-07-02 | 2000-06-30 | Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010232252A Division JP2011041572A (ja) | 1999-07-02 | 2010-10-15 | 核酸合成の感度および特異性の増大のための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003504018A JP2003504018A (ja) | 2003-02-04 |
| JP2003504018A5 true JP2003504018A5 (enExample) | 2007-10-25 |
Family
ID=22498453
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001508332A Pending JP2003504018A (ja) | 1999-07-02 | 2000-06-30 | 核酸合成の感度および特異性の増大のための組成物および方法 |
| JP2010232252A Pending JP2011041572A (ja) | 1999-07-02 | 2010-10-15 | 核酸合成の感度および特異性の増大のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010232252A Pending JP2011041572A (ja) | 1999-07-02 | 2010-10-15 | 核酸合成の感度および特異性の増大のための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1196559B1 (enExample) |
| JP (2) | JP2003504018A (enExample) |
| AT (1) | ATE332371T1 (enExample) |
| AU (1) | AU782555B2 (enExample) |
| CA (1) | CA2377780A1 (enExample) |
| DE (1) | DE60029225T2 (enExample) |
| NZ (1) | NZ516894A (enExample) |
| WO (1) | WO2001002559A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100351393C (zh) | 2001-02-15 | 2007-11-28 | 宝生物工程株式会社 | 核苷酸多态性的检测方法 |
| AU2003267785C1 (en) * | 2002-09-13 | 2009-12-24 | Replicor, Inc. | Non-sequence complementary antiviral oligonucleotides |
| ES2380775T3 (es) * | 2004-10-18 | 2012-05-18 | Brandeis University | Reactivos y procedimientos para mejorar la reproducibilidad y reducir el cebado defectuoso en la amplificación por PCR |
| US8530194B2 (en) | 2005-09-26 | 2013-09-10 | Allelogic Biosciences Corporation | Oligonucleotides as temperature-sensitive inhibitors for DNA polymerases |
| CN101321877B (zh) * | 2005-10-03 | 2013-04-10 | 应用生物系统有限责任公司 | 用于扩增核酸的组合物、方法和试剂盒 |
| US7781165B2 (en) | 2005-10-19 | 2010-08-24 | Roche Diagnostics Operations, Inc. | Benzimidazolium compounds and salts of benzimidazolium compounds for nucleic acid amplification |
| WO2012070618A1 (ja) | 2010-11-24 | 2012-05-31 | 株式会社カネカ | 増幅核酸検出方法及び検出デバイス |
| JP6490576B2 (ja) * | 2012-04-12 | 2019-03-27 | ニユー・イングランド・バイオレイブス・インコーポレイテツド | 重合反応のための合成核酸 |
| US9783844B2 (en) * | 2012-04-27 | 2017-10-10 | Kaneka Corporation | Method for amplifying nucleic acid and method for detecting amplified nucleic acid |
| WO2015076356A1 (ja) * | 2013-11-22 | 2015-05-28 | 株式会社カネカ | 短鎖ｒｎａの検出方法 |
| ES2955993T3 (es) | 2018-01-05 | 2023-12-11 | Hoffmann La Roche | Mejora de la polimerización de los ácidos nucleicos mediante compuestos aromáticos |
| KR102275038B1 (ko) * | 2019-12-11 | 2021-07-08 | (주) 제노텍 | 대립 유전자의 구분성을 높이는 pcr 방법 및 pcr 킷트 |
| WO2021259201A1 (zh) * | 2020-06-22 | 2021-12-30 | 苏州新海生物科技股份有限公司 | 一种核酸配体及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5763173A (en) * | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand inhibitors to DNA polymerases |
| PT833944E (pt) * | 1995-06-07 | 2009-04-14 | Gilead Sciences Inc | Ligandos de ácido nucleico que se ligam a, e inibem, adn-polimerases |
| US5760012A (en) * | 1996-05-01 | 1998-06-02 | Thomas Jefferson University | Methods and compounds for curing diseases caused by mutations |
-
2000
- 2000-06-30 CA CA002377780A patent/CA2377780A1/en not_active Abandoned
- 2000-06-30 AU AU57850/00A patent/AU782555B2/en not_active Ceased
- 2000-06-30 NZ NZ516894A patent/NZ516894A/en unknown
- 2000-06-30 EP EP00943373A patent/EP1196559B1/en not_active Expired - Lifetime
- 2000-06-30 DE DE60029225T patent/DE60029225T2/de not_active Expired - Lifetime
- 2000-06-30 JP JP2001508332A patent/JP2003504018A/ja active Pending
- 2000-06-30 AT AT00943373T patent/ATE332371T1/de not_active IP Right Cessation
- 2000-06-30 WO PCT/US2000/018256 patent/WO2001002559A1/en not_active Ceased
-
2010
- 2010-10-15 JP JP2010232252A patent/JP2011041572A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10704042B2 (en) | Ligation-based RNA amplification | |
| EP3485037B1 (en) | Asymmetric templates and asymmetric method of nucleic acid sequencing | |
| US6114149A (en) | Amplification of mixed sequence nucleic acid fragments | |
| CA2504234C (en) | Process for amplifying nucleic acids | |
| EP3620533B1 (en) | Closed nucleic acid structures | |
| EP3628747B1 (en) | Fabrication of patterned arrays | |
| JP6219944B2 (ja) | ５’保護に依存した増幅 | |
| JP2003504018A5 (enExample) | ||
| CN113227398A (zh) | 在减少的扩增时间下使用巢式重叠引物的指数基数-3核酸扩增 | |
| EP2010670B1 (en) | Method for amplifying unknown dna sequence adjacent to known sequence | |
| EP2496712A1 (en) | Composition and method for synthesizing a deoxyribonucleotide chain using a double stranded nucleic acid complex with a thermostable polymerase | |
| EP3682027B1 (en) | Hybridization-extension-ligation strategy for generating circular single-stranded dna libraries | |
| US20160083724A1 (en) | Methods for sample preparation | |
| AU723202C (en) | Phosphoramidate-phosphodiester oligonucleotide chimera as primers | |
| JP4104285B2 (ja) | Ｄｎａ増幅方法及びそのキット | |
| JP2005503794A (ja) | リボ核酸の増幅 | |
| JPWO1999009213A1 (ja) | Ｄｎａ増幅方法及びそのキット | |
| JPWO2022055984A5 (enExample) | ||
| ENDS | RNA LIGASE-MEDIATED RACE: AN EFFECTIVE | |
| JP2003534772A (ja) | 核酸分子の集団における配列の増幅を選択的に阻害するための方法および組成物 |